On Sept. 9, 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. IRBM will work with MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of the institution’s Therapeutics Discovery division focused on therapeutic antibody development.

The parties collaborated to identify and validate lead antibodies through the pre-clinical proof of concept studies.